Global Blood Therapeutics Profit Margin

Global Blood Therapeutics (GBT) currently reports a profit margin of -138.97% as of June 2022. That compares with -161.55% in the prior-year period — up 14.0% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Global Blood Therapeutics's profit margin history and peer comparisons.

Global Blood Therapeutics's profit margin increased from -161.55% to -138.97% — a 14.0% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Global Blood Therapeutics's profit margin of -138.97% is lower than the Healthcare sector average of 13.89%. That is roughly 1100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Global Blood Therapeutics's current -138.97% should be judged against Healthcare norms (sector average: 13.89%) and against GBT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -138.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Global Blood Therapeutics, and consider following GBT for alerts when major investors trade the stock.